James T. Kenney, RPh, MBA

Authored Items
Realized and Projected Cost-Savings from the Introduction of Generic Imatinib Through Formulary Management in Patients with Chronic Myelogenous Leukemia
David Campbell, PharmD, MS, James T. Kenney, RPh, MBA, Marlo Blazer, PharmD, BCOP, Lisa Bloudek, PharmD, MS, John Brokars, MS, Dinara Makenbaeva, MD, MBA
November 2019 Vol 12, No 7 in Business
Treatment Patterns and Costs of Chronic Inflammatory Demyelinating Polyneuropathy: A Claims Database Analysis
Jeffrey T. Guptill, MD, MA, MHS, James T. Kenney, RPh, MBA, Michael C. Runken, PharmD, Michael Eaddy, PharmD, PhD, Orsolya Lunacsek, PhD, Rupali M. Fuldeore, MS
May 2019 Vol 12, No 3 in Clinical, Original Research
Changes in Medical Services and Drug Utilization and Associated Costs After Narcolepsy Diagnosis in the United States
Kathleen F. Villa, MS, James T. Kenney, RPh, MBA, Nancy L. Reaven, MA, Susan E. Funk, MBA, Karen McGaughey, PhD, Jed Black, MD
May 2018 Vol 11, No 3 in Business, Original Research
Prospective Bundled Payments in a Changing Environment: The Experience of a Self-Funded, State-Sponsored Plan
Frank H. Lawler, MD, MSPH, James T. Kenney, RPh, MBA, Frank R. Wilson, CPA, G. Keith Smith, MD, Lynn V. Mitchell, MD, MPH
December 2017 Vol 10, No 9 in Original Research
The Cost of Hematopoietic Stem-Cell Transplantation in the United States
Michael S. Broder, MD, MSHS, Tiffany P. Quock, MS, PhD, Eunice Chang, PhD, Sheila R. Reddy, PhD, RPh, James T. Kenney, RPh, MBA, Rajni Agarwal-Hashmi, MD, Sally Arai, MD, Kathleen F. Villa, MS
October 2017 Vol 10, No 7 in Business, Original Research
The Medical and Economic Burden of Narcolepsy: Implications for Managed Care
Michael J. Thorpy, MB, ChB, George Hiller, RPh, James T. Kenney, RPh, MBA
July 2017 Vol 10, No 5 in Clinical
Does a Free Office Visit Affect Primary Care–Seeking Behavior? A Study of New Exchange Health Plan Enrollees in Mississippi
James T. Kenney, RPh, MBA, Bettina M. Beech, DrPH, MPH, Tristan Cordier, MPH, Laura E. Happe, PharmD, MPH, Laura Trunk, MD, Gilbert S. Haugh, MS, Richard Kwong, MPH, Vipin Gopal, PhD, Roy A. Beveridge, MD
April 2017 Vol 10, No 2 in Business, Original Research
Health Plans Must Monitor the Oncology Pipeline to Apply Appropriate Coverage Criteria, Maintain Treatment Value
James T. Kenney, RPh, MBA
February 2017 Vol 10, Special Issue: Payers’ Perspectives In Oncology: ASH 2016 Highlights in Payers' Perspectives
The Challenge of Balancing Access to and Paying for New, High-Cost Cancer Therapies
James T. Kenney, RPh, MBA
August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology in Payers' Perspectives
Value-Based Care Must Be Linked to Improved Clinical Outcomes
James T. Kenney, RPh, MBA
February 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology
Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework
James T. Kenney, RPh, MBA, Anuja Roy, PhD, MBA, Jonathan K. Kish, PhD, MPH, Lisa Bloudek, PharmD, MS, David S. Siegel, MD, PhD, Sundar Jagannath, MD, Denise Globe, PhD, Emil T. Kuriakose, MD, Kristen Migliaccio-Walle, BS
June 2015, Vol 8, No 4 in Business
Utilization of Parenteral Anticoagulants and Warfarin: Impact on the Risk of Venous Thromboembolism Recurrence in the Outpatient Setting
Jennifer Cai, MS, MPH, Winghan Jacqueline Kwong, PharmD, PhD, Ronald Preblick, PharmD, MPH, Qiaoyi Zhang, MD, PhD, James T. Kenney, RPh, MBA
November 2014 Vol 7, No 8 in Clinical
The Health and Economic Effects of Counterfeit Drugs
Erwin A. Blackstone, PhD, Joseph P. Fuhr, Jr, PhD, Steve Pociask, MA, James T. Kenney, RPh, MBA
June 2014 Vol 7, No 4 in Business
Payers’ Management of Oncology Drugs: Opportunities and Challenges
James T. Kenney, RPh, MBA
May 2014 Vol 7, No 3
Increasing Importance of Oncology Drug Management for Payers
James T. Kenney, RPh, MBA
July 2013 Vol 6, No 5 in Editorial
Curbing the Costly Trend: Exploring the Need for a Progressive Approach to the Management of Specialty Pharmaceuticals Under the Medical Benefit
Michael S. Jacobs, RPh, James T. Kenney, RPh, MBA, Kjel A. Johnson, PharmD, BcPS, FccP, FAMcP
July/August 2012, Vol 5, No 5 in Business
Impact of the Removal of the Monthly Liver Function Test Requirement for Ambrisentan
Louise A. Durst, RN, James T. Kenney, RPh, MBA, John Carlsen, MHA, Megan Kuchinski, MPH, Lauren Harner, JD, Daniel Neves, BA, Stephanie J. Harris, RN, BSN, Glenna L. Traiger, RN, MSN, CNS-BC
March/April 2012, Vol 5, No 2 in Business
A Call to Action: Responding to the Future Forecasting of Cardiovascular Disease in America
Robert Lee Page ii, PharmD, MSPH, FAHA, FCCP, FASCcP, FASHP, BCPS, Vahram Ghushchyan, PhD, Kavita Nair, PhD, James T. Kenney, RPh, MBA
September 2011, Vol 4, No 5 in Clinical
A Wellness-Based Healthcare System for Chronic Diseases: Prevention, Intervention, and Innovation
Robert E. Henry, Kip Piper, MA, FACHE, F. Randy Vogenberg, PhD, Thomas McCarter, MD, FACP, Farrah N. Daly, MD, MBA, Keri Cooper, Nirav R. Shah, MD,MPH, Lawton Robert Burns, PhD, MBA, Gene Reeder, RPh, PhD, Scott Gottlieb, MD, Toni Fera, BPharm, PharmD, Wayne M. Lednar, MD, PhD, Alberto M. Colombi, MD, MPH, Michael F. Murphy, MD, PhD, Gary M. Owens, MD, James T. Kenney, RPh, MBA, J. B. Jones, PhD, MBA, Walter F. Stewart, PhD, MPH
Supplements
Last modified: April 12, 2019
  • Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME